Eledon Pharmaceuticals (ELDN) Competitors $2.43 +0.06 (+2.53%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.46 +0.03 (+1.23%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. ORKA, ESPR, ARVN, PRME, IVA, OLMA, AQST, CMPS, CMPX, and BCYCShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Oruka Therapeutics (ORKA), Esperion Therapeutics (ESPR), Arvinas (ARVN), Prime Medicine (PRME), Inventiva (IVA), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors Oruka Therapeutics Esperion Therapeutics Arvinas Prime Medicine Inventiva Olema Pharmaceuticals Aquestive Therapeutics COMPASS Pathways Compass Therapeutics Bicycle Therapeutics Eledon Pharmaceuticals (NASDAQ:ELDN) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Does the media favor ELDN or ORKA? In the previous week, Oruka Therapeutics had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 9 mentions for Oruka Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.52 beat Oruka Therapeutics' score of 0.44 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oruka Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in ELDN or ORKA? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ELDN or ORKA more profitable? Oruka Therapeutics' return on equity of -26.26% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -92.51% -38.31% Oruka Therapeutics N/A -26.26%-24.16% Which has more risk & volatility, ELDN or ORKA? Eledon Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Which has better valuation and earnings, ELDN or ORKA? Oruka Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.08Oruka TherapeuticsN/AN/A-$83.72M-$2.81-5.77 Do analysts recommend ELDN or ORKA? Eledon Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 311.52%. Oruka Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 159.10%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryEledon Pharmaceuticals and Oruka Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$141.92M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-2.0821.0376.8026.52Price / SalesN/A249.02448.8087.93Price / CashN/A45.4837.2260.63Price / Book2.319.5614.066.31Net Income-$36.18M-$53.02M$3.29B$271.37M7 Day Performance-4.33%-1.58%-0.77%0.57%1 Month Performance-6.54%2.82%3.84%6.20%1 Year Performance-2.80%9.34%87.65%28.33% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals3.033 of 5 stars$2.43+2.5%$10.00+311.5%-3.6%$141.92MN/A-2.0810Short Interest ↓ORKAOruka Therapeutics2.3738 of 5 stars$15.26-0.9%$40.33+164.3%-38.8%$576.75MN/A-5.43N/ANews CoverageAnalyst ForecastGap UpESPREsperion Therapeutics3.7325 of 5 stars$2.78-2.1%$7.00+151.8%+52.8%$572.61M$332.31M-5.67200ARVNArvinas2.8075 of 5 stars$7.74flat$19.76+155.3%-69.9%$568.26M$372.80M-7.66420News CoverageAnalyst UpgradePRMEPrime Medicine0.517 of 5 stars$4.01-1.5%N/AN/A$547.72M$2.98M0.00N/ANews CoverageGap UpIVAInventiva2.9683 of 5 stars$5.31-5.3%$14.83+179.3%+142.2%$536.67M$9.95M0.00100Upcoming EarningsShort Interest ↑OLMAOlema Pharmaceuticals2.8511 of 5 stars$8.00+3.0%$24.00+200.0%-36.8%$533.29MN/A-4.0470Positive NewsAQSTAquestive Therapeutics1.9826 of 5 stars$5.14+1.8%$10.29+100.1%+0.8%$503.61M$44.13M-7.34160CMPSCOMPASS Pathways3.19 of 5 stars$5.14-1.2%$16.29+216.8%-30.2%$498.89MN/A-2.79120Positive NewsCMPXCompass Therapeutics2.2192 of 5 stars$3.69+3.4%$13.88+276.0%+111.4%$493.67M$850K-8.2020Positive NewsBCYCBicycle Therapeutics3.5248 of 5 stars$6.86-3.0%$22.22+223.9%-71.7%$490M$19.28M-1.95240News Coverage Related Companies and Tools Related Companies ORKA Competitors ESPR Competitors ARVN Competitors PRME Competitors IVA Competitors OLMA Competitors AQST Competitors CMPS Competitors CMPX Competitors BCYC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
